Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Barcoding Center is Early-access Buyer of MBI's Apollo

NEW YORK (GenomeWeb News) – The Canadian Center for DNA Barcoding will use Microchip Biotechnologies’ Apollo 100 STAR tool, which is used for sample preparation for DNA sequencing, MBI said today.
 
The CCDB, which is located at the Biodiversity Institute of Ontario at the University of Guelph, will use MBI’s Apollo system in its efforts to develop a new method of identifying and discovering species that is based on short, standardized gene regions called DNA barcodes.
 
Through an early-access MBI buyer program, the CCDB will use the Apollo system, which is based on microscale-on-chip-valve technology that the company licensed from the University of California. It automatically performs DNA cycle sequencing and bead-based cleanup on microchips, which can reduce labor, lower reagent consumption, and reduce sample processing errors, the company said.
 
CCDB is a member of the International Barcode of Life Project, which aims to build a library of DNA barcodes for 500,000 “socio-economically important species.”
 
Long term, the Barcode of Life Network intends to identify DNA barcodes for all the world’s life forms.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.